Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability (2023 - 2025)

Gyre Therapeutics (GYRE) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $9.6 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 15.66% year-over-year to $9.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.6 million (up 15.66% YoY) and the FY2025 annual result came in at $9.6 million, up 15.66% from the prior year.
• Non-Current Deferred Tax Liability grew to $9.6 million in Q4 2025 per GYRE's latest filing, from $8.3 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $9.6 million in Q4 2025 and bottomed at $2.5 million in Q4 2023.
• The 3-year median for Non-Current Deferred Tax Liability is $8.3 million (2024), against an average of $6.8 million.
• The widest annual swing landed in 2024, when Non-Current Deferred Tax Liability soared 232.0%; it then gained 15.66% in 2025.
• Tracing GYRE's Non-Current Deferred Tax Liability over 3 years: stood at $2.5 million in 2023, then soared by 232.0% to $8.3 million in 2024, then climbed by 15.66% to $9.6 million in 2025.
• Per Business Quant, the three latest GYRE Non-Current Deferred Tax Liability figures stand at $9.6 million (Q4 2025), $8.3 million (Q4 2024), and $2.5 million (Q4 2023).

Peer Comparison